From Seekingalpha · SA Transcripts · · 40s
vTv Therapeutics Discusses Hypoglycemia in Type 1 Diabetes
vTv Therapeutics reveals hypoglycemia burden in type 1 diabetes and cadisegliatin phase 3 progress.
In brief
vTv Therapeutics reveals hypoglycemia burden in type 1 diabetes and cadisegliatin phase 3 progress. vTv Therapeutics discussed hypoglycemia challenges in type 1 diabetes and cadisegliatin phase 3 program during investor event. Originally reported by Seekingalpha.
vTv Therapeutics
vTv Therapeutics Inc. published a slide deck discussing hypoglycemia burden in type 1 diabetes and cadisegliatin phase 3 program.
Investor Event
The slide deck was created for an investor event and published by vTv Therapeutics Inc. on Seeking Alpha.
Cadisegliatin Phase 3
vTv Therapeutics is advancing cadisegliatin through phase 3 clinical trials for type 1 diabetes treatment.
The takeaway
vTv Therapeutics discussed hypoglycemia challenges in type 1 diabetes and cadisegliatin phase 3 program during investor event.
